American Society of Clinical Oncology annual meeting 2015
The annual meeting of the American Society of Clinical Oncology represents the yearly highlight for the world-wide oncologic community. This year saw around 30,000 participants convening in Chicago where they were presented with a wealth of new data.
This years’ motto was “Illumination and Innovation, transforming data into learning”. The hot topics 2015 were the immune-checkpoint-inhibitor therapies especially in malignant melanoma and non-small-cell-lung cancer (NSCLC) as will be high-lighted by Georg Pall. In a subgroup of patients with NSCLC, this new treatment was so effective that it replaced docetaxel as second-line therapy after a first-line regimen including a platinum.